An observational study in Glioblastoma, sponsored by Doo-Sik Kong. Status unknown at 1 site in South Korea. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by Doo-Sik Kong · Observational
This is an exploratory study to evaluate the clinical feasibility of medical deivce 'AVATAMED' for predicting the clinical response to TMZ (temozolomide) in glioblasotma patients.
Glioblastoma patients who would take TMZ treatment will be screened for in vitro drug screening experiment. Patients whose tumor specimen pass the drug screening process will be finally enrolled.
Actual clinical response to TMZ treatment will be compared to drug screening results derived from AVATAMED, a medical software device to predict the drug response based on in vitro assay using patient-derived tumor cells.
1,951 studies on the registry are indexed under Glioblastoma; 457 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 190 observational studies indexed under Glioblastoma.
Browse Glioblastoma studies →This is the only study on the registry with Doo-Sik Kong as lead sponsor.
Counted across the registry records on this site, refreshed daily.
among histologically confirmed glioblastoma patients, patients with samples which passed the QC screening process of in vitro drug screening experiment will be finally enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
6 month PFS rate
the fraction of patients without disease progression at 6 months after the TMZ treatment
Time frame: 6 month
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.